Insulet Corp faces stock decline amid healthcare sector weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Should l Buy PODD?
Source: NASDAQ.COM
Insulet Corp (PODD) has seen a decline of 4.5% as it hits a 20-day low, reflecting broader challenges in the healthcare sector, which is down 1.2% today.
The healthcare sector's overall weakness has impacted investor confidence, with Insulet's stock performance being affected by the sector's decline. Despite being excluded from the Motley Fool's top ten stock picks, analysts still recognize Insulet's long-term growth potential in diabetes management, driven by increasing global demand for innovative treatments.
This decline may prompt investors to reassess their positions in Insulet, especially as the company continues to innovate in the diabetes management space, which remains a critical area of growth in the healthcare market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PODD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PODD
Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 375.83 USD with a low forecast of 316.00 USD and a high forecast of 450.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 243.150
Low
316.00
Averages
375.83
High
450.00
Current: 243.150
Low
316.00
Averages
375.83
High
450.00
About PODD
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Sector Declines 1.2%, Moderna Falls 7.2% Amidst Market Weakness
- Healthcare Sector Decline: As of midday Friday, the healthcare sector is down 1.2%, with Moderna Inc (MRNA) and Insulet Corp (PODD) showing losses of 7.2% and 4.5%, respectively, indicating overall sector weakness that may impact investor confidence.
- ETF Performance Analysis: The Health Care Select Sector SPDR ETF (XLV), which tracks the healthcare sector, is down 0.8% on the day but up 1.48% year-to-date, suggesting that despite short-term volatility, the long-term trend remains positive, potentially attracting investor interest.
- Moderna Year-to-Date Performance: Moderna Inc has risen 63.22% year-to-date, and despite the recent pullback, its strong annual performance may attract long-term investors, especially in the context of ongoing vaccine demand.
- Utilities Sector Performance: The utilities sector is also underperforming, down 1.0%, with AES Corp (AES) and Exelon Corp (EXC) showing declines of 2.7% and 2.0%, respectively, reflecting a weakening demand for defensive stocks in the current market environment.
See More
Insulet (PODD) Analysis: Market Trends and Investment Opportunities
- Market Trend Insights: In the latest Motley Fool Scoreboard episode, analysts delve into Insulet's market dynamics, offering unique insights into future investment opportunities that can help investors capitalize on potential gains.
- Investment Opportunity Assessment: The episode highlights Insulet's innovative products in diabetes management, which are expected to drive future growth, particularly against the backdrop of increasing global demand for diabetes treatments.
- Stock Price Reference: As of December 3, 2025, Insulet's stock price stood at 1.23%, reflecting a cautiously optimistic market outlook on its future performance, prompting investors to monitor its long-term growth potential.
- Video Content Sharing: The video, published on January 20, 2026, aims to provide viewers with the latest market analysis and investment advice, fostering a deeper understanding and interest in Insulet.
See More
Insulet (NASDAQ: PODD) Excluded from Motley Fool's Top 10 Stock Picks
- Investment Recommendation Absence: Insulet was not included in the latest top ten stock picks by the Motley Fool analyst team, indicating a cautious market sentiment regarding its future performance, which may affect investor confidence.
- Historical Return Comparison: The Motley Fool's average return of 955% significantly outperforms the S&P 500's 196%, demonstrating the effectiveness of its stock selection strategy, and Insulet's exclusion may suggest a lack of short-term appeal.
- Market Trend Analysis: Analysts emphasize current market trends and potential investment opportunities; although Insulet is not recommended, its long-term growth potential in the medical device sector remains noteworthy.
- Investor Community Engagement: The Motley Fool encourages individual investors to join its community to share investment insights; despite Insulet's absence from the recommendation list, investors can still access valuable information and advice through the community.
See More
S&P 500 Hits Record High as Data Storage Stocks Lead Gains
- Market Recovery: The S&P 500 index rose by 0.16% to reach a record high, while the Nasdaq 100 increased by 0.08% to a 2.25-month peak, indicating strong demand for data storage and chip manufacturing stocks.
- Surge in Metal Prices: Gold and silver prices soared to all-time highs, driving mining stocks higher, with Hecla Mining and Coeur Mining gaining over 8% and 5% respectively, reflecting strong investor interest in precious metals.
- Economic Data Focus: The market is set to focus on upcoming economic data releases, including December CPI and PPI, which are expected to influence future monetary policy amid political pressures on the Federal Reserve.
- Earnings Season Kickoff: S&P 500 companies are projected to see an 8.4% earnings growth in Q4, while excluding the Magnificent Seven tech giants, earnings growth is expected at 4.6%, providing crucial signals for investors.
See More
Prestige Consumer Acquires Pillar5 Pharma to Expand Eye Care Product Line
- E-Commerce Growth: Prestige Consumer reported double-digit consumption growth in e-commerce channels, with online sales representing up to 20% of total sales in fiscal 2025, reflecting the success of its digital strategies and enhancing market competitiveness.
- Acquisition Fuels Growth: The company announced the acquisition of Pillar5 Pharma, expected to close in Q3 of fiscal 2026, which will enhance supply capabilities in the eye care category, securing near-term supply and expanding long-term production capacity, thereby diversifying its product portfolio.
- Stable Solvency: As of the end of Q2 fiscal 2026, Prestige Consumer reported no short-term debt and cash equivalents of $119 million, indicating a robust financial position that helps mitigate risks from economic fluctuations.
- Cost Pressure Challenges: Despite facing approximately $5 million in tariff costs and supply chain disruptions, Prestige Consumer is proactively implementing cost-saving measures and tactical pricing strategies to offset these impacts, ensuring sustained profitability.
See More
Insulet's Omnipod 5 Platform Achieves Over $200 Million in International Revenue
- Market Share Growth: Insulet's Omnipod 5 platform achieved over $200 million in international revenue for the first time in Q3 2025, driven by rapid product adoption and increasing market demand, significantly enhancing the company's competitive position.
- Surge in U.S. Revenue: U.S. Omnipod revenues grew by 25.6% year-over-year, exceeding the high end of the company's guidance, indicating sustained strong demand for Omnipod 5 among both Type 1 and Type 2 diabetes patients, further expanding the company's market share.
- Strong Financial Health: As of Q3 2025, Insulet reported cash and cash equivalents of $757.4 million with current debt of $80 million, showcasing robust financial stability amid economic uncertainty, which supports future expansion and investment.
- Ongoing Strategic Investments: Insulet is increasing investments in platform innovation, including sensor integrations with Dexcom and Abbott, which are expected to further enhance its technological advantage and drive growth in global markets.
See More
Healthcare Sector Declines 1.2%, Moderna Falls 7.2% Amidst Market Weakness
- Healthcare Sector Decline: As of midday Friday, the healthcare sector is down 1.2%, with Moderna Inc (MRNA) and Insulet Corp (PODD) showing losses of 7.2% and 4.5%, respectively, indicating overall sector weakness that may impact investor confidence.
- ETF Performance Analysis: The Health Care Select Sector SPDR ETF (XLV), which tracks the healthcare sector, is down 0.8% on the day but up 1.48% year-to-date, suggesting that despite short-term volatility, the long-term trend remains positive, potentially attracting investor interest.
- Moderna Year-to-Date Performance: Moderna Inc has risen 63.22% year-to-date, and despite the recent pullback, its strong annual performance may attract long-term investors, especially in the context of ongoing vaccine demand.
- Utilities Sector Performance: The utilities sector is also underperforming, down 1.0%, with AES Corp (AES) and Exelon Corp (EXC) showing declines of 2.7% and 2.0%, respectively, reflecting a weakening demand for defensive stocks in the current market environment.
See More
Insulet (PODD) Analysis: Market Trends and Investment Opportunities
- Market Trend Insights: In the latest Motley Fool Scoreboard episode, analysts delve into Insulet's market dynamics, offering unique insights into future investment opportunities that can help investors capitalize on potential gains.
- Investment Opportunity Assessment: The episode highlights Insulet's innovative products in diabetes management, which are expected to drive future growth, particularly against the backdrop of increasing global demand for diabetes treatments.
- Stock Price Reference: As of December 3, 2025, Insulet's stock price stood at 1.23%, reflecting a cautiously optimistic market outlook on its future performance, prompting investors to monitor its long-term growth potential.
- Video Content Sharing: The video, published on January 20, 2026, aims to provide viewers with the latest market analysis and investment advice, fostering a deeper understanding and interest in Insulet.
See More
Insulet (NASDAQ: PODD) Excluded from Motley Fool's Top 10 Stock Picks
- Investment Recommendation Absence: Insulet was not included in the latest top ten stock picks by the Motley Fool analyst team, indicating a cautious market sentiment regarding its future performance, which may affect investor confidence.
- Historical Return Comparison: The Motley Fool's average return of 955% significantly outperforms the S&P 500's 196%, demonstrating the effectiveness of its stock selection strategy, and Insulet's exclusion may suggest a lack of short-term appeal.
- Market Trend Analysis: Analysts emphasize current market trends and potential investment opportunities; although Insulet is not recommended, its long-term growth potential in the medical device sector remains noteworthy.
- Investor Community Engagement: The Motley Fool encourages individual investors to join its community to share investment insights; despite Insulet's absence from the recommendation list, investors can still access valuable information and advice through the community.
See More
S&P 500 Hits Record High as Data Storage Stocks Lead Gains
- Market Recovery: The S&P 500 index rose by 0.16% to reach a record high, while the Nasdaq 100 increased by 0.08% to a 2.25-month peak, indicating strong demand for data storage and chip manufacturing stocks.
- Surge in Metal Prices: Gold and silver prices soared to all-time highs, driving mining stocks higher, with Hecla Mining and Coeur Mining gaining over 8% and 5% respectively, reflecting strong investor interest in precious metals.
- Economic Data Focus: The market is set to focus on upcoming economic data releases, including December CPI and PPI, which are expected to influence future monetary policy amid political pressures on the Federal Reserve.
- Earnings Season Kickoff: S&P 500 companies are projected to see an 8.4% earnings growth in Q4, while excluding the Magnificent Seven tech giants, earnings growth is expected at 4.6%, providing crucial signals for investors.
See More
Prestige Consumer Acquires Pillar5 Pharma to Expand Eye Care Product Line
- E-Commerce Growth: Prestige Consumer reported double-digit consumption growth in e-commerce channels, with online sales representing up to 20% of total sales in fiscal 2025, reflecting the success of its digital strategies and enhancing market competitiveness.
- Acquisition Fuels Growth: The company announced the acquisition of Pillar5 Pharma, expected to close in Q3 of fiscal 2026, which will enhance supply capabilities in the eye care category, securing near-term supply and expanding long-term production capacity, thereby diversifying its product portfolio.
- Stable Solvency: As of the end of Q2 fiscal 2026, Prestige Consumer reported no short-term debt and cash equivalents of $119 million, indicating a robust financial position that helps mitigate risks from economic fluctuations.
- Cost Pressure Challenges: Despite facing approximately $5 million in tariff costs and supply chain disruptions, Prestige Consumer is proactively implementing cost-saving measures and tactical pricing strategies to offset these impacts, ensuring sustained profitability.
See More
Insulet's Omnipod 5 Platform Achieves Over $200 Million in International Revenue
- Market Share Growth: Insulet's Omnipod 5 platform achieved over $200 million in international revenue for the first time in Q3 2025, driven by rapid product adoption and increasing market demand, significantly enhancing the company's competitive position.
- Surge in U.S. Revenue: U.S. Omnipod revenues grew by 25.6% year-over-year, exceeding the high end of the company's guidance, indicating sustained strong demand for Omnipod 5 among both Type 1 and Type 2 diabetes patients, further expanding the company's market share.
- Strong Financial Health: As of Q3 2025, Insulet reported cash and cash equivalents of $757.4 million with current debt of $80 million, showcasing robust financial stability amid economic uncertainty, which supports future expansion and investment.
- Ongoing Strategic Investments: Insulet is increasing investments in platform innovation, including sensor integrations with Dexcom and Abbott, which are expected to further enhance its technological advantage and drive growth in global markets.
See More
